Theracurmin Supplementation May be a Therapeutic Option for Older Patients with Alzheimer's Disease: A 6-Month Retrospective Follow-Up Study.
Current Alzheimer research, vol.18, no.14, pp.1087-1092, 2021 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 18 Issue: 14
- Publication Date: 2021
- Doi Number: 10.2174/1567205019666211221125255
- Journal Name: Current Alzheimer research
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Abstracts in Social Gerontology, Chemical Abstracts Core, EMBASE, MEDLINE, Psycinfo
- Page Numbers: pp.1087-1092
- Keywords: Acetylcholinesterase inhibitors, Alzheimer's disease, elderly, theracurmin, curcumin, mild cognitive impairment
- Dokuz Eylül University Affiliated: Yes
Abstract
Background: Alzheimer's Disease (AD) is still a great global challenge and agents with various mechanisms represent a promising therapeutic opportunity. Theracurmin, a very highly absorbable curcumin formulation, was shown to improve memory and attention in non-demented people.